Robert Jones, MD, PhD, of the University of Glasgow & Beatson West of Scotland Cancer Centre, Glasgow, UK, reviews key updates on prostate cancer treatments. Speaking at the 2019 Genitourinary Cancers Symposium, held in San Francisco, CA, Prof. Jones gives an overview of the current status of immunotherapies and anti-androgens in the treatment of prostate cancer. In addition, he reviews the results from two promising Phase III studies: the ARAMIS trial (NCT02200614), evaluating the efficacy of darolutamide in non-metastatic castration resistant-prostate cancer (nmCRPC), and the ARCHES trial (NCT02677896) looking at the use of enzalutamide in metastatic hormone-sensitive prostate cancer (mHSPC).

свернуть